Galecto, Inc. GLTO · Stock Open Galecto, Inc. in new tab
Galecto, Inc. Analysis (GLTO)
Is Galecto, Inc. a good investment? Galecto, Inc. (GLTO) is currently trading at 21.58 USD. Market analysts have a consensus price target of 46.75 USD. This suggests a potential upside from current levels.
Earnings Schedule: Galecto, Inc. is expected to release its next earnings report on Aug. 5, 2026. The market consensus estimate for Forward EPS is -0.95.
Investor FAQ
Does Galecto, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Galecto, Inc.?
Galecto, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 5, 2026. The company currently has a trailing EPS of -12.11.
Company Profile
Damora Therapeutics, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. It develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. The company was founded in 2011 and is headquartered in Copenhagen, Denmark.
| Split Date | Split Ratio to 1 |
|---|---|
| Aug. 30, 2024 | 0.040000 |
Community Discussion